These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 3713757

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Adverse drug event reporting. Improving the low US reporting rates.
    Edlavitch SA.
    Arch Intern Med; 1988 Jul; 148(7):1499-503. PubMed ID: 3382293
    [No Abstract] [Full Text] [Related]

  • 3. Physician knowledge, attitudes, and behavior related to reporting adverse drug events.
    Rogers AS, Israel E, Smith CR, Levine D, McBean AM, Valente C, Faich G.
    Arch Intern Med; 1988 Jul; 148(7):1596-600. PubMed ID: 3382304
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Direct-to-consumer advertising of prescription drugs: balancing benefits and risks, and a way forward.
    Kravitz RL, Bell RA.
    Clin Pharmacol Ther; 2007 Oct; 82(4):360-2. PubMed ID: 17851573
    [No Abstract] [Full Text] [Related]

  • 6. Postmarketing surveillance.
    Oleen MA.
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [Abstract] [Full Text] [Related]

  • 7. The black box warning.
    Abourjaily HM, Rosenberg M.
    J Mass Dent Soc; 2002 Oct; 51(3):54-6. PubMed ID: 12380043
    [No Abstract] [Full Text] [Related]

  • 8. National adverse drug reaction surveillance. 1986.
    Faich GA, Dreis M, Tomita D.
    Arch Intern Med; 1988 Apr; 148(4):785-7. PubMed ID: 3355297
    [Abstract] [Full Text] [Related]

  • 9. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA, Brushwood DB.
    J Health Law; 2000 Apr; 33(3):383-454. PubMed ID: 11184355
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reporting adverse drug therapy results.
    Pa Med; 1990 Jun; 93(6):29. PubMed ID: 2367135
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM, Tanner LA, Milstien JB.
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [Abstract] [Full Text] [Related]

  • 14. The practitioner's role in detection of adverse drug reactions.
    Soffer A.
    Arch Intern Med; 1985 Feb; 145(2):232-3. PubMed ID: 3838430
    [No Abstract] [Full Text] [Related]

  • 15. Adverse drug reaction reporting system: developing a well-monitored program.
    Kilarski DJ, Ziegler B, Coarse J, Buchanan C.
    Hosp Formul; 1986 Sep; 21(9):949-52. PubMed ID: 10289704
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Postmarketing follow-up: physicians have key role.
    Goldsmith MF.
    JAMA; 1985 Oct 25; 254(16):2217. PubMed ID: 4046146
    [No Abstract] [Full Text] [Related]

  • 18. Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point.
    Corre KA, Spielberg TE.
    Ann Emerg Med; 1988 Feb 25; 17(2):145-9. PubMed ID: 3257365
    [Abstract] [Full Text] [Related]

  • 19. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
    Ehrenpreis ED, Ciociola AA, Kulkarni PM, FDA-Related Matters Committee of the American College of Gastroenterology.
    Am J Gastroenterol; 2012 Apr 25; 107(4):501-4. PubMed ID: 22475958
    [No Abstract] [Full Text] [Related]

  • 20. Package inserts, adverse drug reactions, and the physician's liability.
    Morrell MX.
    Ration Drug Ther; 1975 Aug 25; 9(8):1-6. PubMed ID: 1144773
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.